Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Working Capital Changes (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Other Working Capital Changes for 14 consecutive years, with -$5.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 188.15% year-over-year to -$5.4 million, compared with a TTM value of -$878000.0 through Dec 2025, down 108.84%, and an annual FY2025 reading of -$878000.0, down 108.84% over the prior year.
  • Other Working Capital Changes was -$5.4 million for Q4 2025 at Heron Therapeutics, down from $5.2 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $8.6 million in Q1 2025 and bottomed at -$9.5 million in Q2 2023.
  • Average Other Working Capital Changes over 5 years is $49950.0, with a median of $25000.0 recorded in 2023.
  • Peak annual rise in Other Working Capital Changes hit 3775.68% in 2025, while the deepest fall reached 3118.69% in 2025.
  • Year by year, Other Working Capital Changes stood at $2.7 million in 2021, then skyrocketed by 75.19% to $4.7 million in 2022, then plummeted by 203.58% to -$4.9 million in 2023, then soared by 226.06% to $6.2 million in 2024, then crashed by 188.15% to -$5.4 million in 2025.
  • Business Quant data shows Other Working Capital Changes for HRTX at -$5.4 million in Q4 2025, $5.2 million in Q3 2025, and -$9.3 million in Q2 2025.